BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24454811)

  • 1. Silencing of CHD5 gene by promoter methylation in leukemia.
    Zhao R; Meng F; Wang N; Ma W; Yan Q
    PLoS One; 2014; 9(1):e85172. PubMed ID: 24454811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma.
    Zhao R; Wang N; Huang H; Ma W; Yan Q
    Liver Int; 2014 Jul; 34(6):e151-60. PubMed ID: 24529164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages.
    Fatemi M; Paul TA; Brodeur GM; Shokrani B; Brim H; Ashktorab H
    Cancer; 2014 Jan; 120(2):172-80. PubMed ID: 24243398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHD5, a tumor suppressor that is epigenetically silenced in lung cancer.
    Zhao R; Yan Q; Lv J; Huang H; Zheng W; Zhang B; Ma W
    Lung Cancer; 2012 Jun; 76(3):324-31. PubMed ID: 22186629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHD5 is down-regulated through promoter hypermethylation in gastric cancer.
    Wang X; Lau KK; So LK; Lam YW
    J Biomed Sci; 2009 Oct; 16(1):95. PubMed ID: 19840376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.
    Du Z; Li L; Huang X; Jin J; Huang S; Zhang Q; Tao Q
    Oncotarget; 2016 Apr; 7(16):21618-30. PubMed ID: 26943038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer.
    Wu X; Zhu Z; Li W; Fu X; Su D; Fu L; Zhang Z; Luo A; Sun X; Fu L; Dong JT
    Breast Cancer Res; 2012 May; 14(3):R73. PubMed ID: 22569290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.
    Fujita T; Igarashi J; Okawa ER; Gotoh T; Manne J; Kolla V; Kim J; Zhao H; Pawel BR; London WB; Maris JM; White PS; Brodeur GM
    J Natl Cancer Inst; 2008 Jul; 100(13):940-9. PubMed ID: 18577749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer.
    Gorringe KL; Choong DY; Williams LH; Ramakrishna M; Sridhar A; Qiu W; Bearfoot JL; Campbell IG
    Neoplasia; 2008 Nov; 10(11):1253-8. PubMed ID: 18953434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma.
    Xie CR; Li Z; Sun HG; Wang FQ; Sun Y; Zhao WX; Zhang S; Zhao WX; Wang XM; Yin ZY
    Oncotarget; 2015 Dec; 6(38):40940-52. PubMed ID: 26517514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer.
    Mulero-Navarro S; Esteller M
    Epigenetics; 2008; 3(4):210-5. PubMed ID: 18698156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNA expression and epigenetic-based role of chromodomain helicase DNA-binding 5 in hepatocellular carcinoma.
    Heidari Z; Asemi-Rad A; Moudi B; Mahmoudzadeh-Sagheb H
    J Int Med Res; 2022 Jul; 50(7):3000605221105344. PubMed ID: 35808817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma.
    Wang J; Chen H; Fu S; Xu ZM; Sun KL; Fu WN
    Oral Oncol; 2011 Jul; 47(7):601-8. PubMed ID: 21636313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region.
    Ortmann CA; Burchert A; Hölzle K; Nitsche A; Wittig B; Neubauer A; Schmidt M
    Nucleic Acids Res; 2005; 33(21):6895-905. PubMed ID: 16396836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of ADAMTS18 by aberrant promoter hypermethylation contribute to lung cancer progression.
    Zhang Y; Xu H; Mu J; Guo S; Ye L; Li D; Peng W; He X; Xiang T
    J Cell Physiol; 2019 May; 234(5):6965-6975. PubMed ID: 30417422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer.
    Kulak MV; Cyr AR; Woodfield GW; Bogachek M; Spanheimer PM; Li T; Price DH; Domann FE; Weigel RJ
    Oncogene; 2013 Aug; 32(34):4043-51. PubMed ID: 22964634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHD5 is a potential tumor suppressor in non small cell lung cancer (NSCLC).
    Baykara O; Tansarikaya M; Bulut P; Demirkaya A; Buyru N
    Gene; 2017 Jun; 618():65-68. PubMed ID: 28400267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5.
    Cai C; Ashktorab H; Pang X; Zhao Y; Sha W; Liu Y; Gu X
    PLoS One; 2012; 7(1):e29750. PubMed ID: 22235338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Methylation of CHD5 Gene Promoter Regulates p19
    Wu MC; Jiang M; Dong T; Lv J; Fang JY; Xu L; Wei ZL; Zhang Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1001-1007. PubMed ID: 31418348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers.
    Zou B; Chim CS; Zeng H; Leung SY; Yang Y; Tu SP; Lin MC; Wang J; He H; Jiang SH; Sun YW; Yu LF; Yuen ST; Kung HF; Wong BC
    Gastroenterology; 2006 Dec; 131(6):1835-43. PubMed ID: 17087954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.